Bieżący numer
Archiwum
Filmy
Artykuły w druku
O czasopiśmie
Suplementy
Rada naukowa
Recenzenci
Bazy indeksacyjne
Prenumerata
Kontakt
Zasady publikacji prac
Opłaty publikacyjne
Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
|
1/2/2004
vol. 106 streszczenie artykułu:
Przedmowa
Wpływ rilmenidyny na ciśnienie wewnątrzgałkowe u królików. Interakcja z efaroksanem i rauwolscyną.
Marta Misiuk-Hojło
1
,
Marek Szaliński
1
,
Anna Merwid-Ląd
2
,
Małgorzata Trocha
2
,
Małgorzata Pieśniewska
2
Data publikacji online: 2004/02/21
Pełna treść artykułu
Pobierz cytowanie
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Purpose Glaucoma is the main cause of blindness in the developed countries. Its progress can be diminished by decreasing intraocular pressure (IOP) using pharmacological or surgical treatment. Antiglaucoma agents, α2 – adrenergic's receptor agonists have been known for several years as IOP lowering. Due to the fact that the majority of them turned out to be imidazoline receptor agonists, it is worth checking if selective imidazoline receptor (I1) agonists alter IOP. Preliminary animal experiments show that they lower IOP. In our study we examined the influence of rilmenidine, a potent I1 receptor agonist, on IOP in rabbits. Furthermore, we tried to find out whether I1 and α2 receptor antagonists (efaroxan and rauwolscine) counteract the pharmacological effect of rilmenidine. Material and methods The study was conducted on adult male White New Zealand rabbits. All the substances were administered topically, and IOP was measured by applanation tonometry after topical anaesthesia before and 1, 3 and 5 hours after drug instillation. Results Rilmenidine showed the lowering effect on IOP at the concentration of 0,4%. Efaroxan and rauwolscine partly inhibited rilmenidine effect. Conclusions Rilmenidine is a potential antiglaucoma agent, though further studies are necessary słowa kluczowe:
ciśnienie wewnątrzgałkowe, rilmenidyna, efaroksan, rauwolscyna, jaskra, badania na zwierzętach |
|